MCOLN1 and neoplasm: Moreover, reduced IFN and TNF production was observed in primary NK cells after treatment with the TRPML1 antagonist, ML-SI3, at 10 and 50 μΜ, followed by K562 tumor cell challenge (Fig. 5H).